Starton Holdings (STA US)

Starton Holdings, Inc. is a clinical-stage biotechnology company that uses its proprietary continuous delivery technology platform to improve standard-of-care cancer therapies. The company is conducting an initial public offering to fund the development of its lead product candidates, STAR-LLD, which are continuous delivery systems of lenalidomide for various hematologic malignancies.